Here’s the truth most articles won’t tell you upfront: a bone marrow transplant is a type of stem cell transplant. The confusion is understandable because clinicians, patients, and even medical literature use these terms loosely. But when your oncologist says “bone marrow transplant” versus “peripheral blood stem cell transplant” versus “cord blood transplant,” they’re describing three different source methods for the same basic goal — replacing your damaged hematopoietic (blood-forming) cells with healthy ones.
Wondering about donor eligibility and repeat donations? See how many times you can donate bone marrow.
The key differences between a bone marrow transplant and a stem cell transplant come down to where the cells are harvested, how quickly they engraft, the risk profile for graft-versus-host disease (GVHD), and which patients benefit most from each approach. These clinical implications matter enormously — they can influence everything from survival rates to long-term quality of life. Let’s break it all down.
What Exactly Is the Difference?
All three procedures fall under the umbrella term hematopoietic stem cell transplant (HSCT). The distinction is the source of stem cells:
- Bone marrow transplant (BMT): Stem cells are surgically aspirated from the donor’s pelvic bones (posterior iliac crest) under general or regional anesthesia. This was the original method, first performed successfully in 1968.
- Peripheral blood stem cell transplant (PBSCT): The donor receives injections of granulocyte colony-stimulating factor (G-CSF) for 4–5 days to mobilize stem cells from the marrow into the bloodstream. Cells are then collected via apheresis — no surgery required.
- Cord blood transplant (CBT): Stem cells are harvested from the umbilical cord and placenta immediately after birth and cryopreserved in cord blood banks.
Today, roughly 75% of allogeneic transplants in adults use peripheral blood as the stem cell source, according to CIBMTR (Center for International Blood and Marrow Transplant Research) data. Bone marrow harvest accounts for about 20%, and cord blood makes up the remainder.
Head-to-Head Comparison: 7 Key Differences
| Feature | Bone Marrow Transplant | Peripheral Blood Stem Cell Transplant | Cord Blood Transplant |
|---|---|---|---|
| Cell source | Pelvic bone (iliac crest) | Circulating blood after G-CSF | Umbilical cord/placenta |
| CD34+ cell dose | ~2–3 × 10⁶/kg | ~5–8 × 10⁶/kg | ~0.2–0.5 × 10⁶/kg |
| Neutrophil engraftment | ~21 days | ~14–16 days | ~25–30 days |
| Platelet engraftment | ~25 days | ~18–20 days | ~40–60 days |
| Acute GVHD risk | Moderate (~40%) | Moderate-high (~45–50%) | Lower (~25–30%) |
| Chronic GVHD risk | Lower (~30–35%) | Higher (~50–60%) | Lowest (~15–25%) |
| HLA matching required | 8/8 preferred | 8/8 preferred | 4–6/6 acceptable |
Why the Source Matters Clinically
Engraftment Speed
Peripheral blood stem cell transplants deliver a significantly higher dose of CD34+ cells, which translates to faster neutrophil and platelet recovery. For patients with active infections or severe cytopenias, those extra 5–7 days can be life-saving. Faster engraftment also means shorter hospital stays and reduced transfusion needs.
GVHD Risk: The Trade-Off
PBSCT comes with more T lymphocytes — roughly 10 times more than bone marrow grafts. That higher T-cell dose accelerates engraftment but also drives chronic GVHD rates up substantially. A landmark randomized trial by Anasetti et al. (2012, NEJM) involving 551 patients found that bone marrow transplant recipients had significantly lower rates of chronic GVHD (53% vs. 67%) compared to PBSCT, with no difference in overall survival at 2 years.
This is why many pediatric transplant centers still prefer bone marrow as the default source — children face decades of potential GVHD-related morbidity.
Cord Blood: The Underdog With Unique Advantages
Cord blood requires less stringent HLA matching (4/6 vs. 8/8), making it invaluable for patients from ethnic minorities who are underrepresented in donor registries. The trade-off is slower engraftment and higher graft failure rates. Double cord blood transplants — using two units — have helped overcome the cell dose limitation in adults.
Common Indications for Transplant
- Acute myeloid leukemia (AML) — the most common indication for allogeneic HSCT
- Acute lymphoblastic leukemia (ALL) — especially high-risk or relapsed disease
- Myelodysplastic syndromes (MDS) — the only curative option
- Severe aplastic anemia — bone marrow is generally preferred over PBSCT here due to lower GVHD risk
- Inherited disorders — sickle cell disease, thalassemia major, severe combined immunodeficiency (SCID)
- Relapsed lymphomas — typically autologous PBSCT
Autologous vs. Allogeneic: Another Layer
Don’t confuse the source question with the donor question. An autologous transplant uses the patient’s own stem cells (almost always from peripheral blood). An allogeneic transplant uses cells from a matched donor — sibling, unrelated donor, or cord blood. Autologous transplants carry no GVHD risk but also lack the beneficial graft-versus-tumor effect.
About 60% of all HSCTs performed annually in the U.S. (~14,000 of ~23,000) are autologous, primarily for multiple myeloma and lymphoma.
When to Talk to Your Doctor
If transplant is being discussed as part of your treatment plan, ask these specific questions:
- Which stem cell source do you recommend for my diagnosis, and why?
- What is my estimated risk of acute and chronic GVHD with each source?
- Do I have a matched sibling donor, or will we need an unrelated donor search?
- Am I a candidate for a reduced-intensity (non-myeloablative) conditioning regimen?
- What is the expected engraftment timeline, and how long will I be hospitalized?
If you’ve been told you need a transplant and haven’t been referred to a transplant center accredited by FACT (Foundation for the Accreditation of Cellular Therapy), request that referral. Outcomes are measurably better at high-volume centers performing more than 40 transplants per year.
Frequently Asked Questions
Is a bone marrow transplant more painful than a stem cell transplant?
For the donor, yes — bone marrow harvest requires anesthesia and causes hip soreness for 1–2 weeks. PBSC donation involves 4–5 days of G-CSF injections (which cause bone aches and flu-like symptoms) and a 4–6 hour apheresis session. For the recipient, both are infused intravenously and feel similar to a blood transfusion.
Which transplant type has a higher survival rate?
Overall survival is comparable between bone marrow and PBSCT for most malignant diseases. The Anasetti trial showed no significant difference in 2-year survival. However, the quality of survival differs — chronic GVHD after PBSCT can cause debilitating skin, eye, liver, and lung problems for years.
Can you have a stem cell transplant without a perfect donor match?
Yes. Haploidentical transplants (half-matched, typically a parent or child) have become increasingly successful since the introduction of post-transplant cyclophosphamide protocols. Cord blood also allows for partial mismatches. These options have dramatically expanded access — today, virtually every patient who needs a transplant can find a donor.
How long does recovery take after a stem cell transplant?
Expect 2–4 weeks for initial engraftment, 3–6 months before returning to normal activities, and 1–2 years for full immune reconstitution. PBSCT recipients typically leave the hospital a few days earlier than BMT recipients, but chronic GVHD can extend recovery significantly.
Why do doctors still use the term “bone marrow transplant” if most transplants use peripheral blood?
Habit and patient recognition. “Bone marrow transplant” has been in the medical vocabulary since the 1960s. Many transplant programs still carry the name even though the majority of their procedures use peripheral blood stem cells. The field is gradually shifting to the more accurate umbrella term: hematopoietic cell transplant (HCT).
